ÄãÉí±ßÊÇ·ñÓмÒÈ˳öÏÖ²»×ÔÖ÷µÄÕð²ü¡¢ÊÖ¶¶¡¢ÐÐ×ßʱ²½×Ó±äС¼°Æ½ºâÄÜÁ¦±ä²îµÈÇé¿öÄØ£¿ÕâÖ»ÊÇССµÄ벡Â𣿲»£¡×÷Ϊһ¸öºÏ¸ñµÄ¼ÒÈË£¬Ç§Íò²»ÄܺöÊÓÉí±ßÈ˳öÏÖÕâЩ±ä»¯£¬ºÜ¿ÉÄÜÊÇ¡°±©·çÓꡱ¡ª¡ªÅÁ½ðɲ¡À´ÁÙǰµÄÕ÷Õס£²»¹ÜÊÇ¡°ÈËÃñÒÕÊõ¼Ò¡±¡ª¡ª°Í½ð¡¢ÖøÃûÊýѧ¼Ò³Â¾°Èð¡¢ÀøÖ¾Ð¡¸çÇñ»³µÂ¶¼ÉîÊÜÅÁ½ðɲ¡µÄÕÛÄ¥¡£ÄÇôÅÁ½ðɲ¡µÄ·¢²¡»úÖÆ¼°Ñо¿½øÕ¹ÄãÓÖÁ˽â¶àÉÙÄØ£¿½ÓÏÂÀ´£¬ÕâÆªÎÄÕ½«Îª´ó¼Ò¼òµ¥½éÉÜÅÁ½ðɲ¡µÄÑо¿¸Å¿ö¡£
ÅÁ½ðɲ¡£¨Parkinson's disease £¬PD£©£¬ÊÇÒ»ÖÖ³£¼ûµÄÉñ¾ÍËÐÐÐÔ¼²²¡£¬Ö¢×´°üÀ¨Õð²ü¡¢¼¡ÈâÊÕËõÌÛÍ´ºÍ˵»°À§Äѵȣ¬Æä²¡Àí±íÕ÷ΪºÚÖÊÖÂÃܲ¿¶à°Í°·Éñ¾ÔªµÄËðÉ˼°LewyСÌåµÄÐγɡ£½üÄêÀ´£¬ÅÁ½ðɲ¡µÄ·¢²¡ÄêÁäÔ½À´Ô½ÄêÇữ¡£Ñо¿±íÃ÷£¬PD¿ÉÄÜÓë»·¾³¼°ÒÅ´«ÒòËØÓйأ¬È籩¶ÓÚ¶¾ËØMPTP¡¢SNCAÍ»±ä¡¢LRRK2Í»±ä¶¼»áµ¼ÖÂPDµÄ·¢Éú¡£Ä¿Ç°Ñо¿ÏÔʾ£¬PDµÄ·¢²¡»úÖÆ°üÀ¨¦Á-Í»´¥ºËµ°°×¾Û¼¯¡¢ÌúËÀÍöÑõ»¯Ó¦¼¤¡¢Éñ¾Ñ×Ö¢¡¢ÏßÁ£Ì幦ÄÜÕϰºÍ³¦µÀÉú̬ʧµ÷¡£ÕâЩ·Ö×Ó»úÖÆÖ®¼äµÄÏ໥×÷ÓÃʹPDµÄ·¢²¡»úÖÆ¸´ÔÓ»¯£¬´Ó¶øÊ¹Õë¶ÔPDµÄÖÎÁÆÑ§¼°Ò©ÎïÑо¿½øÕ¹»ºÂý£¨Í¼2£©£¬ÔÚÕâЩ·¢²¡»úÖÆÑо¿¹ý³ÌÖУ¬Ïà¹ØµÄÅÁ½ðɶ¯ÎïÄ£ÐÍ·¢»Ó×Ų»ÈݺöÊÓµÄ×÷Óá£
ÅÁ½ðɲ¡£¨Parkinson's disease £¬PD£©£¬ÊÇÒ»ÖÖ³£¼ûµÄÉñ¾ÍËÐÐÐÔ¼²²¡£¬Ö¢×´°üÀ¨Õð²ü¡¢¼¡ÈâÊÕËõÌÛÍ´ºÍ˵»°À§Äѵȣ¬Æä²¡Àí±íÕ÷ΪºÚÖÊÖÂÃܲ¿¶à°Í°·Éñ¾ÔªµÄËðÉ˼°LewyСÌåµÄÐγɡ£½üÄêÀ´£¬ÅÁ½ðɲ¡µÄ·¢²¡ÄêÁäÔ½À´Ô½ÄêÇữ¡£Ñо¿±íÃ÷£¬PD¿ÉÄÜÓë»·¾³¼°ÒÅ´«ÒòËØÓйأ¬È籩¶ÓÚ¶¾ËØMPTP¡¢SNCAÍ»±ä¡¢LRRK2Í»±ä¶¼»áµ¼ÖÂPDµÄ·¢Éú¡£Ä¿Ç°Ñо¿ÏÔʾ£¬PDµÄ·¢²¡»úÖÆ°üÀ¨¦Á-Í»´¥ºËµ°°×¾Û¼¯¡¢ÌúËÀÍöÑõ»¯Ó¦¼¤¡¢Éñ¾Ñ×Ö¢¡¢ÏßÁ£Ì幦ÄÜÕϰºÍ³¦µÀÉú̬ʧµ÷¡£ÕâЩ·Ö×Ó»úÖÆÖ®¼äµÄÏ໥×÷ÓÃʹPDµÄ·¢²¡»úÖÆ¸´ÔÓ»¯£¬´Ó¶øÊ¹Õë¶ÔPDµÄÖÎÁÆÑ§¼°Ò©ÎïÑо¿½øÕ¹»ºÂý£¨Í¼1£©£¬ÔÚÕâЩ·¢²¡»úÖÆÑо¿¹ý³ÌÖУ¬Ïà¹ØµÄÅÁ½ðɶ¯ÎïÄ£ÐÍ·¢»Ó×Ų»ÈݺöÊÓµÄ×÷Óá£

ͼ 1 PD¼²²¡ºÍÖÎÁƵĻù´¡Ñо¿ºÍÒ©Î↑·¢Ê·
PDµÄ¶¯ÎïÄ£ÐÍÖ÷ÒªÓÐÒÅ´«ÒòËØÓë»·¾³ÒòËØ±©Â¶ÓÕµ¼Ä£ÐÍ£¬ÏÂÃæ¸ø´ó¼Ò½éÉܼ¸ÖÖ³£ÓõÄÄ£ÐÍÓ¦ÓÃʵÀý£º
(1) »ùÒòÓÕµ¼PDÄ£ÐÍ£ºBenoit IµÈÈËͨ¹ý¹¹½¨ÈËÔ´¦Á-Í»´¥ºËµ°°×£¨h¦Á-syn£©µÄPrnp-SNCA*A53Tת»ùÒòСÊ󣬷¢ÏÖ¸Ãת»ùÒòСÊóÔÚ7¸öÔÂǰÔ˶¯ÄÜÁ¦Õý³££¬¶ø´Ó8¸öÔ¿ªÊ¼£¬²¿·ÖСÊóÖð½¥³öÏÖÔ˶¯ÕϰµÄ±íÐÍ£¬ÔÚ14-15¸öÔÂʱ£¬¾ø´ó²¿·ÖСÊó¶¼³öÏÖ²»Í¬³Ì¶ÈµÄÔ˶¯Õϰ£¨Í¼2£©¡£

ͼ 2 hA53T ¦Á-synת»ùÒòСÊóÔÚÀÏÄêʱÆÚ³öÏÖÔ˶¯Õϰ
(2) »·¾³ÒòËØ±©Â¶ÓÕµ¼PDÄ£ÐÍ£ºShuang-Feng XuµÈÈ˲ÉÓÃÁ¬Ðø5Ì츹ǻעÉäMPTP£¨30 mg/kg/day£©µÄ·½·¨¹¹½¨PDСÊóÄ£ÐÍ£¬²¢¸¹Ç»×¢ÉäÈéÌúµ°°×£¨Lf£©½øÐÐÖÎÁÆ¡£½á¹û·¢ÏÖLf¿É»º½âMPTPÓÕµ¼µÄÔ˶¯Õϰ£¨Í¼3£©¡£

ͼ 3 Lf¿É»º½âMPTPÓÕµ¼µÄÔ˶¯Õϰ
×÷Õß½øÒ»²½Í¨¹ýÃâÒßȾɫ·ÖÎöÀÒ°±ËáôÇ»¯Ã¸£¨TH£¬¶à°Í°·µÄǰÌ壩ºÍ¶à°Í°·×ªÔ˵°°×£¨DAT£©ÔÚÖÐÄÔºÚÖʺÍÎÆ×´ÌåÇøÓòµÄ±í´ïÇé¿ö£¬½á¹û±íÃ÷LfÖÎÁƼõÇáÁËMPTPÓÕµ¼µÄDAÉñ¾ÔªËðÉË£¨Í¼4£©¡£

ͼ 4 LfÖÎÁƼõÇáÁËMPTPÓÕµ¼µÄDAÉñ¾ÔªËðÉË
³ýÒÔÉÏÁ½ÖÖ¶¯ÎïÄ£ÐÍ£¬PD³£Óõ͝ÎïÄ£ÐÍ»¹ÓÐÒÔϼ¸ÖÖ£¨±í1£©£º
±í 1 PD³£Óõ͝ÎïÄ£ÐÍ
Ä£ÐÍ | ÔìÄ£·½·¨ |
ÂýÐÔÓãÌÙͪÓÕµ¼Ä£ÐÍ | 8ÖÜC57ÐÛÊó¿Ú·þÓãÌÙͪ£¨30 mg/kg/Ì죩£¬³ÖÐø4ÖÜ |
ÎÆ×´ÌåÄÚ×¢Éä¦Á-syn PFFÄ£ÐÍ | 3ÔÂÁä´ÆÐÛСÊóÎÆ×´ÌåÄÚ×¢Éä¦Á-syn PFF£¬30Ìì×óÓÒ³öÏÖÏàÓ¦µÄ²¡ÀíÑ§ÌØÕ÷¼´ÎÆ×´ÌåÄÚ¦Á-Í»´¥ºËµ°°×¾Û¼¯ |
ת»ùÒòÄ£ÐÍ | Ö÷ÒªÓÐSNCA¡¢PINK1¡¢LRRK2¡¢DJ-1£¬PRKNµÈ |
ÔÚ¹¹½¨ÕâЩģÐ͵Ĺý³ÌÖУ¬ÎÒÃÇÔõô¼ø¶¨Ä£ÐÍÊÇ·ñ³É¹¦ÄØ£¿ÈçÒÔÉÏÎÄÏ×ËùÊö£¬ÔÚ²¡Àí·½Ãæ£¬ÎÒÃÇ¿ÉÒÔͨ¹ýÃâÒßȾɫ¹Û²ìºÚÖÊÖÂÃÜÇø¶à°Í°·Éñ¾ÔªËðÉËÇé¿ö£¬ÈçÀÒ°±ËáôÇ»¯Ã¸£¨TH£¬¶à°Í°·µÄǰÌ壩ºÍ¶à°Í°·×ªÔ˵°°×£¨DAT£©µÄ±í´ï¡£ÁíÒ»·½Ã棬ÎÒÃÇ¿ÉÒÔͨ¹ýÏàÓ¦µÄÐÐΪѧÀ´ÆÀ¹ÀÄ£ÐÍÊÇ·ñ³É¹¦£¬Ö÷ÒªÓÐÒÔϼ¸ÖÖ³£ÓõÄÐÐΪѧ£º
¿õ³¡ÊµÑ飺¿õ³¡ÏäΪ40 cm¡Á40 cm¡Á40 cmµÄ²»Í¸Ã÷ËÜÁϺУ¨Í¼5£©£¬½«Ð¡Êó·ÅÈë¿õ³¡ÏäÖÐ×ÔÓÉ̽Ë÷5 min£¬¼Ç¼СÊóǰ5 minÄÚÔ˶¯µÄ×ܾàÀë¡¢ÔÚÖÐÐÄÇøÓòÔ˶¯µÄ¾àÀ롢СÊóµÄÔ˶¯¹ì¼£¡£

ͼ 5 ¿õ³¡ÊµÑéÏä
ת°ôʵÑ飺ʵÑé×°ÖÃÈçͼ6Ëùʾ¡£Ð¡ÊóÔÚÊÔÑéǰ3Ìì½øÐÐѵÁ·£¬ÊµÑéµ±Ì콫СÊóÖÃÓÚ¼ÓËÙÐýתԲÖùÌåÉÏ£¬²¢²âÁ¿¶¯ÎïµÄÍ£ÁôÔÚÔ²ÖùÌåÉϵÄʱ¼ä¡£ËÙ¶ÈÔÚ 5 ·ÖÖÓÄÚ´Ó 4 rpm »ºÂýÔö¼Óµ½ 40 rpm¡£Èç¹ûСÊó´ÓÌݼ¶ÉϵôÏÂÀ´»òץסÉ豸²¢Á¬ÐøÐýת 2 Ȧ¶ø²»³¢ÊÔÔÚÌݼ¶ÉÏÐÐ×ߣ¬ÔòÊÔÑé½áÊø¡£Ð¡ÊóÒÔ30 minµÄ¼ä¸ô½øÐÐ3´ÎÁ¬ÐøÊµÑ飬²âÊÔÊý¾ÝСÊóÔÚÐýת¸ËÉÏÍ£Áôʱ¼äµÄƽ¾ùÖµ¡£

ͼ 6 ת°ôÒÇ
ÅÀ¸Ë²âÊÔ£º½«Ò»¸ù³¤¶ÈΪ50 cm¡¢Ö±¾¶Îª3 cmµÄľ¸Ë¹Ì¶¨·ÅÖÃÔÚËÇÑøÁý×ÓÖУ¬°ÑСÊó·ÅÖÃÔÚ¸Ë×Ó¶¥²¿£¨¾àÀë¸Ë¶¥²¿7.5 cm£©£¬Í·³¯ÉÏ£¬¼Ç¼СÊýµ½´ï¸Ëµ×²¿µÄʱ¼ä£¬ÔÚ²âÊÔ֮ǰ£¬Á¬ÐøÑµÁ·Ð¡ÊóÁ½Ì죬ÿ´Î3´ÎѵÁ·²âÊÔ£¬ÔÚ²âÊÔµ±Ì죬ÿֻСÊó½øÐÐ3´ÎÖØ¸´ÊµÑ飬¼Ç¼СÊóתÍä¡¢ÅÀÉý¼°×Üʱ¼ä¡£
×¥Á¦²âÊÔ£ºÊµÑé×°ÖÃÈçͼ7£¬ÊµÑéʱ½«Ð¡Êó·ÅÖÃÔÚ½ðÊôÍø¸ñÉÏ£¬Ê¹Æäǰ֫»òÕßǰºóÖ«×¥×¡Íø¸ñ£¬ÇáÇáÀ¶¯Î²°Í£¬µ±Ð¡ÊóËÉ¿ª¶ÔÍø¸ñµÄ×¥ÎÕʱ£¬¼Ç¼Á¦´«¸ÐÆ÷ÉϵÄÁ¦£¨g£©£¬Ã¿Ö»Ð¡ÊóÁ¬Ðø½øÐÐ3´Î¡£

ͼ 7×¥Á¦²âÊÔÒÇ
³ýÁËÒÔÉÏ4Öг£ÓõÄÐÐΪѧʵÑ飬ÓÉÓÚÅÁ½ðɲ¡Ò²»áÒýÆðÐÄÀí½¡¿µÎÊÌ⣬Ñо¿ÕßÒ²»áͨ¹ýYÃÔ¹¬¡¢Ç¿ÆÈÓÎÓ¾µÈʵÑéÀ´ÆÀ¹ÀÄ£ÐͶ¯ÎïµÄ½¹ÂǼ°ÒÖÓôˮƽ¡£
»¶Ó¸÷λ¿ÆÑй¤×÷ÕßЯÊÖÁé¸³ÍØÆÕ£¬Ò»Æð¹¥¿Ë¡°²»ËÀ°©Ö¢¡±¡ª¡ªÅÁ½ðɹ²Í¬¿ªÕ¹ÅÁ½ðɲ¡µÄ»úÖÆ¼°Ò©ÎïÑо¿~
±¾ÆÚ·ÖÏí¾Íµ½ÕâÀ²£¬¸ü¶à´óС¶¯ÎïÉñ¾Ä£ÐÍÒÔ¼°´ó¶¯ÎïÄ£Ð͵È֪ʶ»¶ÓÖµç 0755-86325431 .Á鸳w88winÓŵ½߳ÏΪÄú·þÎñ¡£
²Î¿¼ÎÄÏ×
1. Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023 Feb 21;8(1):73. doi: 10.1038/s41392-023-01353-3. PMID: 36810524; PMCID: PMC9944326. IF 39.3
2. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002 May 16;34(4):521-33. doi: 10.1016/s0896-6273(02)00682-7. PMID: 12062037. IF 16.2
3. Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, Kim S, Oh N, Kim NA, Lee S, Brahmachari S, Mao X, Lee JH, Kumar M, An D, Kang SU, Lee Y, Lee KC, Na DH, Kim D, Lee SH, Roschke VV, Liddelow SA, Mari Z, Barres BA, Dawson VL, Lee S, Dawson TM, Ko HS. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med. 2018 Jul;24(7):931-938. doi: 10.1038/s41591-018-0051-5. Epub 2018 Jun 11. PMID: 29892066; PMCID: PMC6039259. IF 82.9
4. Zhao Z, Ning J, Bao XQ, Shang M, Ma J, Li G, Zhang D. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021 Nov 17;9(1):226. doi: 10.1186/s40168-021-01107-9. PMID: 34784980; PMCID: PMC8597301. IF 15.5